

WO 2004/110984 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110984 A1

(51) International Patent Classification?: C07C 235/20,
A61K 31/16, A61P 3/00

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(21) International Application Number:
PCT/SE2004/000964

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BJ, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 16 June 2004 (16.06.2004)

Declaration under Rule 4.17:

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0314129.8 18 June 2003 (18.06.2003) GB

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EG, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, IS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BJ, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

(71) Applicant (*for all designated States except US*): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

Published:

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): AURELL, Carl-Johan [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). DAHLSTRÖM, Mikael [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINDBECKT-ALSTERMARK, Eva-Lotte [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). MINIDIS, Anna [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). OHLSSON, Bengt [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). STÄHLE, Erica [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EG, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, IS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BJ, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICALLY USEFUL SALTS OF CARBOXYLIC ACID DERIVATIVES

(57) Abstract: A compound selected from one or more of the following: a (1*R*,2*S*)-2-hydroxyindan-1-amine salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl)propanoic acid; an L-arginine salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxyphenyl)propanoic acid; a *tert*-butylamine salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxyphenyl)propanoic acid; a choline salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl)propanoic acid; an adamantanamine salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl)propanoic acid; a *N*-benzyl-2-(benzylamino)ethanaminium salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl)propanoic acid; a *N*-benzyl-2-(benzylamino)ethanaminium salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl)propanoic acid; or a tris(hydroxymethyl)methylamine salt of (2*S*)-2-ethoxy-3-(4-[2-(hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl)propanoic acid.